Since the advent of the iPSC technology, enormous progress has been made. Human iPSCs have been widely used for disease modeling, drug discovery, and cell therapy development. Novel mechanisms have been elucidated, drugs have started to enter clinical trials, and increasing number of clinical trials have been initiated. The combination of iPSC technology with gene editing and organoids makes it even more powerful. We propose to have an iPSC symposium in 2026 to celebrate achievements we have made in the iPSC field, reflect on lessons we have learnt, and identify challenges and opportunities for moving forward. The important concepts for the symposium include iPSC-based disease modeling and drug discovery, iPSC-based cell therapy development (autologous and universal donors), clinical trials of iPSC-derived products, 3D modeling using organoids or organs-on-a-chip, and AI and machine learning in iPSC research and applications, as well as bioethics. Such a meeting on iPSCs will provide a great opportunity for researchers, clinicians, industrial experts, and investors to interact, creating unusual collaborative prospects. It could transform the field through sharing knowledge from different disciplines, leading to the development of new cellular platforms and therapeutic products, which will ultimately impact clinical practice positively. This symposium will appeal to a wide community, including researchers, clinicians, industrial partners, and venture capitalists.